IOL CHEMICALS & PHARMACEUTICALS LTD. Q4 FY25 Results
IOLCPQ4 FY25 ResultsAnnounced 16 May 2025, 07:06 pm| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 527.78 | 0.9% |
| Total Income | 532.31 | 0.9% |
| Expenditure | 487.61 | 2.4% |
| PBT | 44.70 | 60.8% |
| Net Profit | 31.42 | 53.0% |
| OPM | 11.89% | 11.78pp |
| NPM | 5.90% | 2.01pp |
| EPS | 1.07 | 69.4% |
IOL Chemicals & Pharmaceuticals Ltd. Delivers Strong Q4 Performance with 17% EBITDA and 12% PAT Growth
16 May 2025 · 16 May 2025, 09:32 pm
Summary
IOL Chemicals & Pharmaceuticals Ltd. has announced its audited financial results for the quarter and year ended 31st March 2025, showing a 17% growth in EBITDA and 12% growth in PAT year-on-year. The company has also reported operational highlights such as the successful commissioning of a new Paracetamol production unit and strategic investments in capacity enhancement.
Key Highlights
- 1
Revenue from Operations: 527.8 Cr (Q4 FY25), 2,079.2 Cr (FY25)
- 2
EBITDA: 67.5 Cr (Q4 FY25), 224.6 Cr (FY25)
- 3
Profit After Tax: 31.6 Cr (Q4 FY25), 101.0 Cr (FY25)
- 4
Successfully commissioned Unit-11 for Paracetamol at the Barnala facility
- 5
Expanded Clopidogrel Bisulphate capacity from 180 MTPA to 240 MTPA
- 6
Received EDQM Certification of Suitability (CEPs) for Mesalazine and Quetiapine Fumarate
- 7
Secured approval from China’s National Medical Products Administration (NMPA) to export Ibuprofen
- 8
Acquired 101 acres along the Chandigarh-Bathinda Highway for future expansion
Management Comments
Mr Vikas Gupta
Joint Managing Director
In Q4FY25, we delivered sustainable performance, with the Ibuprofen segment showing improved traction despite intense competition and continued pricing pressure in global markets. A key highlight was the successful commissioning of our fully backward-integrated Paracetamol production unit, with an installed capacity of 10,800 MTPA. This has tripled our Paracetamol capacity, enabling us to strengthen our non-Ibuprofen portfolio, particularly in high-demand, fast-moving therapeutic categories. Notably, pricing and demand across our broader API basket remained stable. However the chemicals segment delivered stable performance despite muted volumes, as enhanced operational efficiencies across key units contributed to a notable improvement in EBIT. FY25 was marked by strategic consolidation and investments focused on capacity enhancement, improved utilization, cost control, and regulatory expansion. Our strong backward integration model continues to drive cost control, supply reliability, and operating leverage. We remain committed to strengthening our portfolio, driving operational excellence, and expanding our market reach to create sustained value.
Informational and educational content only. Not investment advice.